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Abstract
Immunization of hypercholesterolemic mice with selected apoB-100 peptide antigens reduces atherosclerosis but the
precise immune mediators of athero-protection remain unclear. In this study we show that immunization of apoE (-/-) mice
with p210, a 20 amino acid apoB-100 related peptide, reduced aortic atherosclerosis compared with PBS or adjuvant/carrier
controls. Immunization with p210 activated CD8
+ T cells, reduced dendritic cells (DC) at the site of immunization and within
the plaque with an associated reduction in plaque macrophage immunoreactivity. Adoptive transfer of CD8
+ T cells from
p210 immunized mice recapitulated the athero-protective effect of p210 immunization in naı ¨ve, non-immunized mice. CD8
+
T cells from p210 immunized mice developed a preferentially higher cytolytic response against p210-loaded dendritic cells
in vitro. Although p210 immunization profoundly modulated DCs and cellular immune responses, it did not alter the
efficacy of subsequent T cell dependent or independent immune response to other irrelevant antigens. Our data define, for
the first time, a role for CD8
+ T cells in mediating the athero-protective effects of apoB-100 related peptide immunization in
apoE (-/-) mice.
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Introduction
Adaptive and innate immunity have been implicated in
atherogenesis and pre-clinical studies have suggested that
immuno-modulating therapies can reduce atherosclerosis [1,2].
One such strategy involves active immunization using apoB-100
related peptide antigens [3,4].
Although active immunization using several different apoB-
100 peptides reduces atherosclerosis [1,3–5], the humoral or
cellular immune mediators of such effect have not been fully
elucidated. Recent reports show that different immunization
strategies using the same peptide antigen (apoB-100 related
peptide p210) yield different immune responses, yet still
provide protection against atherosclerosis [6,7]. Subcutaneous
immunization of LDLR(-/-)/human apoB-100 transgenic mice
with p210 did not elicit an increase of anti-p210 antibody
response compared with carrier control but reduced athero-
sclerosis by 59% [6]. No specific mechanism was delineated in
the report. On the other hand, intranasal immunization of
apoE(-/-) mice with a p210-CTB fusion protein preparation
reduced atherosclerosis by 35% with increased IgG titers
against p210 and CD4
+ T regulatory cells without further
elucidation of the role of either immune response [7].
Nevertheless, both studies concluded that the protection
against atherosclerosis was independent of p210 antibody
response. Thus how the immune response to p210 immuniza-
tion mediates protection against atherosclerosis still remains
largely unknown.
In this study, we therefore designed a series of experiments to
characterize the immune response to p210 immunization and to
define the type of immune cells that mediate the athero-protective
effect of p210 immunization.
Results
p210 immunization reduced atherosclerosis
Immunization with p210 reduced aortic atherosclerosis by 57%
and 50% compared to PBS and cBSA/Alum group, respectively
(Fig. 1A) without significant difference in circulating cholesterol
levels or body weight (Table 1). The aortic sinus plaques from
p210/cBSA/alum group contained significantly reduced macro-
phage and dendritic cell (DC) immuno-reactivity assessed by
MOMA-2 (Fig. 1B) and CD11c (Fig. 1C) immunohistochemical
staining respectively with no difference in the aortic sinus lesion
size (Table 1). There was no difference in CD4
+ T cells, but a
significant reduction in CD8
+ T cells in both the cBSA/Alum
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30780Figure 1. p210 immunization confers protection against atherosclerosis. Representative pictures of aortic en-face lipid staining from each
group shown (A; left panel). Immunization with native p210 resulted in a significant reduction in aortic atherosclerosis when compared to PBS and
cBSA/Alum group (A; right panel; n=9–10 each group). P210 immunization significantly reduced macrophage infiltration (B) assessed by MOMA-2
stain (n=9–10 each group) and DC presence (C) assessed by CD11c (n=7–12 each group) stain in aortic sinus plaques. Positive stain indicated by
reddish-brown color. Data were analyzed by ANOVA followed by Newman-Keuls multiple group comparison, *P,0.05 vs. PBS and cBSA/alum.
doi:10.1371/journal.pone.0030780.g001
Table 1. Circulating level of cholesterol and body weight of mice from PBS, cBSA/alum and p210/cBSA/alum group at euthanasia.
PBS cBSA/alum P210/cBSA/alum P value (ANOVA)
Cholesterol (mg/dl; N=10) 15036485 13956420 11356381 NS
Body weight (gm; N=10) 37.965.4 34.865.4 34.366.5 NS
Aortic sinus plaque size (mm
2; N=10) 0.4060.13 0.4260.09 0.4060.08 NS
Aortic sinus plaque CD4
+ (% area; N$5) 0.2160.21 0.1760.15 0.3660.26 NS
Aortic sinus plaque CD8
+ (% area; N$5) 0.5260.35 0.1160.25* 0.2160.27* 0.03
*P,0.05 vs. PBS (post-hoc test).
doi:10.1371/journal.pone.0030780.t001
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(Table 1).
Characterization of response to p210 immunization
Antibody response to p210 immunization. IgM levels
against p210 were low in all groups prior to immunization at 6–
7 weeks of age. There was a significant increase in p210 IgM
titer in all groups at euthanasia at 25 weeks of age (Fig. 2A),
suggesting an immune response against endogenous p210. To
verify if p210 is indeed a self-antigen that elicits an antibody
response, we performed dot-blot assays to test the reactivity of
serum IgM from p210-immunized mice on purified human
apoB-100 and mouse liver protein extract with p210 as positive
and PBS as negative controls, respectively. Dot blots showed
serum IgM reactivity to human apoB-100 and mouse liver
extract (Fig. 2B).
IgG antibodies against p210 were low in all 3 groups of mice
prior to immunization. At euthanasia at 25 weeks of age, there was
a significant increase in p210 IgG antibodies in both cBSA/alum
and p210/cBSA/alum groups compared with the PBS group, but
levels in the cBSA/alum group was the highest between the 2
responding groups (Fig. 2C). The increase in IgG antibodies
against p210 in both cBSA/alum group and p210/cBSA/alum
but not in the PBS group suggests that immunoglobulin class
switching occurred in response to the adjuvant.
CD4
+ T cell response to immunization. One week after
the primary immunization, splenic CD4
+ T cells and CD4
+CD69
+
T cells were similar among the 3 groups (not shown), but
CD4
+CD62L
+ T cells (Fig. 3A) were significantly reduced in
cBSA/alum group compared to PBS and p210/cBSA/alum
groups. This was coupled with a significantly increased
CD4
+CD25
+IL-10
+ T cell population in the cBSA/alum group.
However, this increased response was significantly attenuated by
p210/cBSA/alum immunization to levels comparable to PBS
(Fig. 3B). Splenic CD4
+CD25
+IL-12
+ T cells did not differ among
the three groups (not shown). Thus, significant changes in the
CD4
+ T cell population occurred in the cBSA/alum group but not
specific to the p210/cBSA/alum group.
CD8
+ T cell response to immunization. At the same time-
point, splenic CD8
+ T cells and CD8
+CD69
+ T cells were similar
among the 3 groups (not shown) but the CD8
+CD62L
+ Tc e l l
population was significantly increased in the p210/cBSA/alum
group (Fig. 3C). This occurred as CD8
+CD25
+IL-10
+ Tc e l l si n
p210/cBSA/alum group was also significantly increased when
compared to PBS or cBSA/alum groups (Fig. 3D). There were no
differences in CD8
+CD25
+IL-12
+ T cells among the 3 groups
(not shown). CD8
+CD25
+ T cells were also similar among the 3
groups. Thus, p210 immunization elicited a CD8
+ Tc e l l
response.
We also evaluated the percentage of CD4
+ or CD8
+ T cells and
CD25 expression from mice euthanized at 13 or 25 weeks and
observed no difference among the 3 groups specific to p210
immunization (not shown).
T cell response to p210 in vitro. T cell proliferation using
CFSE was assessed in spleens of immunized WT mice stimulated
with p210 three weeks after the second booster injection (Figure
S1). WT mice were used to assure that potential antigenic
exposure from serum cholesterol as confounding factors would be
kept at a minimum given the severe levels of hypercholesterolemia
in apoE-/- mice. Stimulation with p210 increased CD4
+ T cell
proliferation in both cBSA/alum and p210/cBSA/alum
compared to PBS. CD8
+ T cell proliferation was selectively
highest in p210/cBSA/alum immunized mice compared to PBS
and cBSA/alum.
Effect of p210 immunization on dendritic cells
Since DCs were significantly reduced in the plaques of p210-
immunized mice at euthanasia, DCs were assessed by flow
cytometry at other sites at earlier time points. Cells from the
subcutaneous immunization sites were isolated one week after the
primary immunization or the second booster. The PBS group
could not be included in this analysis because mice receiving PBS
injection did not develop swelling or cell accumulation at the
injection site. There were significantly fewer CD11c
+ cells in
p210/cBSA/alum group compared to cBSA/alum group at the
immunization site 1 week after the primary immunization
(Fig. 4A). CD11c
+ cells in the lymph nodes were not different 1
week after the primary immunization (not shown), but were
significantly reduced 1 week after the second booster in the p210/
cBSA/alum group (Fig. 4B).
To determine if the DCs in the p210/cBSA/alum group
changed in phenotype, CD86 expression was analyzed in the
Figure 2. Antibody response to p210 immunization. (A) P210
IgM antibody levels were low before immunization and significantly
increased at euthanasia with no difference among the 3 groups of mice.
(B) Immune-reactivity of serum IgM from p210/cBSA/alum mice against
dot blot of human apoB-100 and mouse liver protein extract. (C) P210
IgG antibody levels were low before immunization and remained low in
the PBS group at euthanasia but significantly increased in cBSA/alum
and p210/cBSA/alum groups, with the highest levels in the cBSA/alum
group. N=5 each for 6–7 week time-point and n=9 each for 25 week
time-point. Data were analyzed by ANOVA followed by Newman-Keuls
multiple group comparison, *P,0.05 vs. PBS; {P,0.05 vs. cBSA/alum.
doi:10.1371/journal.pone.0030780.g002
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significant increase in the percentage of CD11c-gated CD86
2 cells
in the p210/cBSA/alum group, paralleled by a significant
reduction in the percentage of CD86
+ cells. However, CD86
mean fluorescent intensity among the groups did not change
(Figure S2). The results indicate that immunization reduced the
number of CD11c
+CD86
+ DCs but did not change the cell
phenotype.
Figure 3. Spleen T lymphocyte response to p210 immunization. (A) Representative scatter plots of CD4
+ gated cells expressing CD62L from
spleens of the different groups, and the results plotted in a bar graph showed a significant reduction in the cBSA/alum group. (B) Representative
scatter plots of CD4-gated CD25
+IL-10
+ cells, and the results plotted in a bar graph showed a significant increase in the cBSA/alum group that was
attenuated in the p210/cBSA/alum group. (C) Representative scatter plots of CD8b
+ gated cells expressing CD62L, and the results plotted in a bar
graph showed a significant increase in the p210/cBSA/alum group. (D) Representative scatter plots of CD8b-gated CD25
+IL-10
+ cells, and the results
plotted in a bar graph showed a significant increase in the p210/cBSA/alum group. For all graphs, *P,0.05 vs. other groups; N=5 each; ANOVA
followed by Newman-Keuls multiple group comparison.
doi:10.1371/journal.pone.0030780.g003
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+ T cells
against dendritic cells
Given the observation that p210 immunization elicited a CD8
+ T
cell response and reduced DCs in the immunization sites, lymph
nodes, and atherosclerotic plaques, we hypothesized that CD8
+Tc e l l s
a r et h ee f f e c t o rc e l l so ft h ei m m u n er e s p o n s ew i t hD C sa sap o t e n t i a l
target of lytic activity. To test this, we co-cultured syngeneic apoE (-/-)
bone marrow derived DCs with CD8
+ T cells from the various
experimental groups. CD8
+ T cells from p210 immunized mice
significantly increased the percentage of DC lysis when compared to
those from PBS or cBSA/alum groups (Fig. 5A and left panel of 5B).
Depletion of CD25
+ cells from the CD8
+ T cell pool negated
the lytic activity specific to the p210/cBSA/alum group (Fig. 5B,
middle panel) supporting the notion that CD8
+CD25
+ T cells are
the effector cells of the response to p210 immunization.
The medium used to culture the cells is normally supplemented
with 10% FBS, which contain apoB-100 on the LDL cholesterol
fraction. To test if DC lysis by CD8
+ T cells from the p210/cBSA/
alum group is specific for the presence of lipid-associated antigens
in the medium, the identical lytic assay was performed in 10%
delipidated FBS. Specific lytic activity was lost when the assay was
performed in delipidated FBS medium (Fig. 5B, right panel),
supporting the notion that CD8
+ T cells from the p210/cBSA/
alum group specifically targeted lipid-associated antigens in serum.
Lysis of p210-loaded dendritic cells by p210-immune
CD8
+ T cells
We further assessed lytic activity of CD8
+ T cells from the
different groups against p210-loaded target DCs. To assure that
the peptide was taken up by the DCs, FITC-labeled p210 (p210-
FITC, 100 mg/ml) was incubated with DCs for 18 hours and
visualized using fluorescence microscopy. FITC was detected in
DCs cultured with p210-FITC but not in cells incubated with
FITC alone (Fig. 5C, bottom left panel). Visible light microscopy
assured the FITC signal was localized to the DCs (Fig. 5C, top left
panel). Lytic assay was then performed using p210-FITC loaded
DCs as target cells. Lysis was assessed on FITC-gated DCs to
assure that only p210-FITC loaded DCs were included in the
analysis. Lytic activity was observed only in the DCs co-cultured
with CD8
+ T cells from the p210/cBSA/alum group (Fig. 5D).
Adoptive transfer of p210-immune CD8
+ T cells
recapitulates the effect of p210 immunization
Donor CD8
+T cells from PBS, cBSA/alum, or p210/cBSA/
alum groups were adoptively transferred to 6–7 week-old naive
recipient apoE (-/-) mice. At euthanasia, the recipient mice injected
with CD8
+ T cells from p210/cBSA/alum group developed
significantly less atherosclerotic lesions in the aorta compared to
the recipient mice injected with CD8
+ T cells from PBS or cBSA/
alum groups (Fig. 6A). The reduction in aortic lesions was coupled
with decreased splenic CD11c
+ DCs (PBS group: 4.361.7%;
cBSA/alum group: 3.460.3%; p210/cBSA/alum group: 1.56
0.3%; n=5 each group, P,0.05, p210/cBSA/alum group vs. PBS
or cBSA/alum group). There was no significant difference in
circulating levels of total cholesterol among 3 groups (PBS group:
10836296 mg/dl; cBSA/alum group: 9756401 mg/dl; p210/
cBSA/alum group: 10986379 mg/dl). Aortic sinus plaque size was
similar among the recipient groups. Macrophage presence was
highest in recipients of PBS CD8
+ T cells. There was significantly
Figure 4. p210 immunization reduced DCs in vivo. Represen-
tative scatter plot of viable cells from the immunization site one week
after primary immunization gated on CD11c (A, top panel). Mice that
received PBS injection did not have palpable swelling and cell
accumulation at the injection site, hence not included. Bar graph
shows significantly reduced presence of CD11c
+ DCs at the
immunization site of the p210/cBSA/alum group (A, bottom panel;
N=10each,*P,0.05 by Mann-Whitney test). (B) One week after the
second booster injection, p210 immunized mice had significantly
reduced CD11c
+ DCs in pooled lymph nodes from bilateral axillary
and cervical areas compared to cBSA/alum group (n=5 in each
group; P,0.05; ANOVA followed by Newman-Keuls multiple group
comparison).
doi:10.1371/journal.pone.0030780.g004
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+ T cell presence in the aortic sinus of recipient mice
injected with CD8
+ T cells from p210/cBSA/alum donors
compared to PBS or cBSA/alum group. No difference was
observed in CD8
+ T cells in the aortic sinus (Figure S3).
Depletion of CD8
+CD25
+ T cells nullified the reduction in
atherosclerosis observed in the recipient mice injected with CD8
+
T cells from p210/cBSA/alum group (Fig. 6B), supporting the
notion that the functional T cell population induced by
Figure 5. Increased cytolytic activity of CD8
+ T cells from p210 immunized mice against dendritic cells in vitro. (A) Representative scatter
plot of CD11c-gated cells stained with 7-AAD after co-culture for 4 hours with CD8
+ T cells from the different experimental groups. CD8
+ T cells from p210
immunized mice had a significantly higher cytolytic activity against DCs when compared to those from PBS or cBSA/alum groups (B, left panel; N=11 each;
*P,0.05). Depletion of CD25
+ cells from the CD8
+ T cells negated thelytic activity specific to p210 immunized mice(B, center panel; N=4 each). Specificity
of the increased lytic activity of CD8
+ T cells from p210-immunized mice was also negated by performing the assay in media supplemented with 10%
delipidatedserum(B,right panel;N=3each).(C) Dendritic cells wereable to uptake p210asindicatedby thepresence ofgreenfluorescencein thecell( l e f t
panel). When such dendritic cells were co-cultured with CD8
+ T cells from p210-immunized mice, there was a significant increase of lytic activity when
compared to those from PBS or cBSA/alum groups (right panel). Data were analyzed by ANOVA followed by Newman-Keuls multiple group comparison.
doi:10.1371/journal.pone.0030780.g005
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+CD25
+ T cells. There was also a
lack of difference in CD11c
+ DCs among the recipient groups after
CD8
+CD25
+ depletion (PBS group: 2.960.8%; cBSA/alum
group: 3.161.2%; p210/cBSA/alum group: 2.360.4%; n=8–
10 each group).
Adoptive transfer of B cells isolated from the spleens of p210
immunized donor mice did not affect atherosclerosis in recipient
mice compared to mice receiving B cells from other donors
(Figure S4A). To assess CD4
+CD25
+ T cells as possible athero-
protective mediators induced by sub-cutaneous p210 immuniza-
tion, we adoptively transferred CD4
+CD25
+T cells into naı ¨ve
recipient apoE (-/-) mice. There was no difference in lesion size
among the 3 groups of CD4
+CD25
+ T cell recipients at a dose of
1610
5 cells/mouse or 3610
5 cells/mouse (Figure S4B and C,
respectively).
Immunization with p210 does not affect the adaptive
immune response to other T cell dependent or
independent antigens
Given the observations that p210 immunization decreased
CD11c
+ DCs and reduced adaptive IgG response to p210, we next
tested if such modulation of DCs by p210 immunization would
alter the host immune response to other antigens. KLH was
chosen as a prototypical T cell dependent and TNP as a T cell
independent antigen. We first immunized mice with p210 as
described in previous sections followed by two separate subcuta-
neous KLH immunizations or intra-peritoneal injection of TNP-
LPS. Using the KLH- or TNP-IgG titer as a surrogate for the
efficacy of individual immunization, we found that there was no
difference in KLH- or TNP-IgG titers (Fig. 7A and B, respectively)
between p210 immunized mice and the titers from mice of PBS or
cBSA/alum groups.
Discussion
In this study, we showed that: (a) subcutaneous p210
immunization elicited a functional CD8
+ T cell immune response;
(b) p210 immunization reduces DCs at the immunization sites and
in atherosclerotic plaques; (c) the athero-protective effect of
subcutaneous p210 immunization is mediated by CD8
+ T cells
but not by CD4
+CD25
+ T cells or B cells; and (d) DCs are
potential targets of cytolytic CD8
+ T cells elicited by p210
immunization.
There have been 4 prior publications describing the athero-
protective effect of p210 immunization [4,6–8], but there was no
definitive report regarding the specific cellular immune responses
responsible for such effect of p210 immunization. The two studies
Figure 6. Adoptive transfer of CD8
+ T cells from p210
immunized donors recapitulated the effect of p210 immuni-
zation. (A) CD8
+ T cell recipient mice from p210/cBSA/alum immunized
donors developed significantly smaller atherosclerotic lesions com-
pared to the recipient mice of CD8
+ T cells from other 2 groups (N=9–
10 each group; P,0.05). This effect was negated when CD25
+ cells were
depleted from the donor pool (B; 8–10 each group). Data were analyzed
by ANOVA followed by Newman-Keuls multiple group comparison.
doi:10.1371/journal.pone.0030780.g006
Figure 7. IgG titers against KLH or TNP after p210 immuniza-
tion. (A) Prior immunization with p210 did not affect the efficacy of
subsequent T cell dependent (KLH, n=3–6 each group) or (B) T-cell
independent (TNP, n=4–5 each group) immunization as assessed by
the IgG antibody titers when compared to mice received PBS or cBSA/
alum. Data were analyzed by ANOVA followed by Newman-Keuls
multiple group comparison.
doi:10.1371/journal.pone.0030780.g007
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mechanism [4,6]; whereas Wigren et al. suggested that Tregs are
involved in the response but did not test in vivo the specific cell
type proposed [8]. The study by Klingenberg et al. described
intra-nasal p210 immunization increased splenic CD4
+IL-10
+ T
cells in p210 group when compared to untreated control group but
did not define further the role of splenic CD4
+IL-10
+ T cells in
mediating the effect of intra-nasal p210 immunization [7].
However, the site of antigenic entry, intra-nasal in their study
compared to subcutaneous in our study, will likely yield different
results. The current study systematically delineates the immune
responses after subcutaneous p210 immunization and identifies
CD8
+ T cells as the immune cell type that mediates the protective
effect against atherosclerosis. We further show that targeting DCs
is a potential immune mechanism underlying the protective effect
of immunization with p210 against atherosclerosis.
Active immunization with homologous LDL or apoB-100
related peptides reduces atherosclerotic lesions in experimental
animals [3,4,9–14]. Antibodies elicited by such immunization had
been postulated to be responsible for the athero-protective effect
[13,14]. On the other hand, significant reduction of atherosclerosis
after immunization with native LDL did not depend on high titers
of antibodies against oxidation–specific epitopes in LDL [11]. We
observed that mice immunized with cBSA/alum developed higher
p210 IgG titers than mice immunized with p210/cBSA/alum and
the transfer of B cells from p210/cBSA/alum immunized donors
failed to reduce atheosclerosis in recipient mice. This is in
agreement with a previous study where p210 immunization
resulted in reduced p210 antibody titers compared with the carrier
group [6]. Thus, our results combined with those from the
previous studies strongly suggest that the humoral immune
response is not likely to be responsible for the athero-protection
elicited by p210 immunization. Our results also suggest the
following points: (a) the presence of elevated p210 IgM titers in all
3 groups of mice suggests that atherosclerosis is associated with an
endogenous p210 humoral immune response; (b) CD8
+ T cell
response and p210 IgG titer could be used as markers for an
immune response to p210 but only CD8
+ T cell response would be
an immune marker for efficacy against atherosclerosis.
LDL immunization activates both CD4
+ and CD8
+ T cells [13].
However LDL immunization was effective against atherosclerosis
even in CD4/apoE double knockout mice [15], suggesting CD4
+
T cells are not important mediators of the beneficial effect of LDL
immunization. CD4
+ T cells are pro-atherogenic as evidenced by
the aggravation of atherosclerotic lesions in mice receiving naı ¨ve
or antigen-primed CD4
+ T cells [16,17]. Interestingly, the CD8
+
T cell population increased significantly in CD4/apoE double
knockout mice compared to apoE (-/-) mice [15] but the role of
CD8
+ T cells in mediating the effect of LDL immunization has not
been previously addressed.
A subset of CD4
+ T cells, CD4
+CD25
+ T cells, reduce
atherosclerotic lesions after being adoptively transferred into
recipient mice [18,19]. The recent reports [7,8] on the possible
role of CD4
+CD25
+ T cells in mediating the reduction in p210
immunized mice prompted us to check its role as well. However,
CD4
+CD25
+ T cells are not likely to be responsible for the
beneficial effects of p210 immunization since the CD4
+CD25
+ T
cell recipient group did not recapitulate the athero-protective
effect selective to p210 immunization at the 2 doses tested.
CD8
+ T cells exist in atherosclerotic plaques [20,21] but their
role in atherogenesis has not been defined. The observation that
atherosclerotic lesions in MHC-I deficient mice were significantly
larger than those in wild type mice suggested a possible role of
MHC-I and CD8
+ T cells in atherogenesis [22]. However direct
experimental proof has been lacking. Another recent report
suggested early activation of CD8
+ T cells induced by hypercho-
lesterolemia without delineating specific mechanistic insight [23].
An important finding of our study is that p210 immunization
elicited a prominent CD8
+ T cell response, its significance
highlighted by the reduction of atherosclerosis in mice receiving
CD8
+ T cells from the p210/cBSA/alum immunized donor
group. These observations clearly define the specific role of CD8
+
T cells in mediating the athero-protective effect of p210
immunization and suggest the possible use of CD8
+ T cell
response as a potential marker for the efficacy of p210
immunization. Negation of the reduction in atherosclerosis specific
to p210 after depletion of CD25
+ cells from the donor CD8
+ T
cells further suggest that the CD8
+CD25
+ T cell population is the
effector cell involved in reducing atherosclerosis. In another
arterial injury model, we recently reported that CD8
+ T cells are
activated after arterial injury and are the specific effectors in
modulating neointimal formation [24]. Taken together, these
reports suggest that, in addition to CD4
+ T cells, CD8
+ T cells also
play an important role in modulating arterial responses to various
injury stimulations.
Dendritic cells are present in atherosclerotic plaques [25,26]
and many studies have suggested a pivotal role of DCs in
atherogenesis. Intimal DCs rapidly ingest lipid and become foam
cells when mice are fed hyper-cholesterolemic diet. Depletion of
these intimal DCs reduces foam cell formation [27]. Deficiency of
the chemokine receptor CX3CR1, a regulator of monocyte
adhesion and migration, decreases DC accumulation in the
arterial wall leading to reduced atherosclerosis [28]. Deficiency
of CD11c, a surface marker on DCs, reduced atherosclerotic
lesions as well [29]. Our result showing reduced DCs in the p210-
immunization site, lymph nodes, and plaques suggest that DC is
one of the potential targets of CD8
+ T cell mediated athero-
protective effect of p210 immunization.
The CD8
+ T cells from p210 immunized mice preferentially
increased its cytolytic function compared with those from PBS or
cBSA/alum immunized mice against identical DC targets. The
results clearly establish that p210 immunization specifically altered
CD8
+ T cell function. What remains unclear is how DCs are
targeted by p210 primed CD8
+ T cells. Results from our in vitro
experiments and several prior publications may provide some
insights in this matter. Because p210 is derived from apoB-100, the
cytolytic response is likely against apoB-100 fragments displayed
on MHC class I of the target DCs. The only source of apoB-100 in
our in vitro experiments is the fetal bovine serum (FBS) used for
culture. ApoB-100 in FBS of culture media has been the subject of
investigation by researchers confounded by the immune response
observed in recipients of cell-therapy treatments [30]. Both
experimental and clinical studies showed that the immune system
reacted against the second set of cell therapy injections and elicited
both antibody responses (implicating MHC class II) and cytolytic
responses (implicating MHC class I). Exogenous antigens are
usually processed by the MHC class II pathway. However, antigen
cross-presentation is a well-accepted alternative in endosomal
processing of antigens. Interestingly, mononuclear cells differen-
tiating into DCs increase surface expression of the LDL receptor,
which mediates antigen presentation [31] making the LDL
receptor at least one of possible pathways for uptake. We therefore
speculated that some of the LDL-cholesterol in the FBS would be
taken up by DCs, get processed through the endosomal system and
subsequently be cross-presented to MHC class I and displayed on
the surface of the DCs, thus being recognized and targeted by
p210 primed CD8
+ T cells. Extending the notion that apoB-100
presented by DCs is the antigenic target in our study, removal of
ApoB-100 Peptide and CD8 in Atherosclerosis
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FBS, would predictably reduce the specific cytolytic activity of
CD8
+ T cell from the p210/cBSA/A mice. Our results indeed
show that performing the lytic assay in delipidated serum medium
had this outcome. Loading of target DCs with FITC-labeled p210
further confirmed the lytic activity specific to CD8
+ T cell from the
p210/cBSA/A mice. However at this time we do not know how
p210 is processed in DCs for MHC-I presentation and the exact
sequence of p210 motif on MHC-I molecule. Considering the fact
that DCs are the main cell type that process and present antigens,
another predictable outcome of the targeted lysis of DCs in vivo
would be reduced humoral immune response to the p210 antigen.
Again, the reduced antibody response in the p210 immunized
group compared with the cBSA group is compatible with this
notion.
Whether the reduction of DCs after p210 immunization alters
the immune responses to other antigens was also investigated. This
has an important clinical implication because human subjects
receive multiple vaccinations throughout their life-span. The IgG
titer against KLH (a T cell depenent antigen), or TNP (a T cell
indepenent antigen) post p210 immunization did not differ among
3 groups. Given the intimate interaction among cellular and
humoral immune components for antibody production, this intact
antibody response suggests that the process of antigen recognition
and presentation by DCs, cooperation between the antigen-
specific B and T lymphocytes via various co-stimulatory molecules
and cytokines, isotype switching and cellular migration among
lymphoid organs remain intact in the immune response to
unrelated antigens after p210 immunization.
In conclusion, we have shown that immunization with native
p210 in vivo reduced DCs at the immunization sites and in the
atherosclerotic plaques, reduced macrophage infiltration in the
plaques, and decreased aortic atherosclerosis. More importantly
we show that the athero-protective effect of p210 immunization is
mediated by CD8
+ T cells. Our results not only provide additional
experimental evidence to support the concept of active immuni-
zation using apoB-100 related peptides to modulate atherosclerosis
but also delineate the cell type that mediates such effect.
Materials and Methods
Selection of peptides and their preparation for
immunization
The establishment and screening of human apoB-100 peptides
has been reported [32]. Based on our pilot experiments and prior
reports [33,34], we selected peptide 210 (p210, KTTKQ SFDLS
VKAQY KKNKH) as a candidate immunogen. Native p210
peptide (Euro-Diagnostica AB, Sweden) was conjugated to
cationic bovine serum albumin (cBSA) as carrier using a method
described previously [3,4]. Alum was used as adjuvant and mixed
with peptide/cBSA conjugate with 1:1 ratio in volume. Peptide
conjugation and mixing with alum were freshly prepared prior to
each immunization.
Immunization protocols
Male apoE (-/-) mice (Jackson Laboratories) were housed in a
pathogen-free animal facility accredited by the Association for the
Assessment and Accreditation of Laboratory Animal Care
International and kept on a 12-hour day/night cycle with
unrestricted access to water and food. In a pilot experiment,
p210 immunization using 100 mg dose conferred optimum athero-
reduction compared to 25 or 50 mg dose. Hence 100 mg dose was
used for all subsequent experiments. The Institutional Animal
Care and Use Committee of Cedars-Sinai Medical Center
approved the experimental protocols (IACUC No. 1248, 1563
and 2567).
Mice, maintained on normal chow diet, received subcutaneous
primary immunization in the dorsal area between scapulas at 6–7
weeks of age, followed by a booster at 9 and 12 weeks of age. One
week after last booster, diet was switched to high cholesterol chow
(TD 88137, Harlan-Teklad) and continued until euthanasia at the
age of 25 weeks. Separate groups of mice receiving PBS or cBSA/
alum at the same immunization time-points served as control.
Some mice were sacrificed at 8 or 13 weeks of age to assess
immune response against p210.
Tissue harvesting and preparation
At euthanasia the hearts were harvested and embedded in OCT
compound (Tissue-Tek) for cryo-section. Whole aortas were
cleaned, processed and stained with Oil-red-o to assess the extent
of atherosclerosis en face with computer-assisted histomorphometry
[3,4].
Immunohistochemistry and histomorphometry
The sections from aortic sinus were stained with MOMA-2
(Serotec), CD11c, CD4, or CD8b (eBioscience) antibody to
identify macrophages, dendritic cells, or T cells immunohisto-
chemically using standard protocol. Oil-red-o stain for plaque size
was done using standard protocol. Computer-assisted morpho-
metric analysis was performed on samples blinded to the person to
assess histomorphometry as described previously [3,4]. The person
who performed the computer-assisted analysis was blinded toward
to the treatment of the mice.
Serum ELISA
Flat-bottomed 96-well polystyrene plates (MaxiSorp, Germany)
were pre-coated with 100 ul (20 mg/ml) P210, KLH, TNP-KLH
(Biosearch Technologies T-5060) or BSA (2 mg/ml for IgG or
10 mg/ml for IgM) respectively by incubation overnight at 4uCt o
assess antibody levels using standard protocol. The coating
concentration and serum dilution was optimized in pilot
experiments. Goat anti-mouse HRP -IgG (Pierce 31437) or IgM
(Southern Biotech) were used as detecting antibodies and the
bound antibodies were detected by developing in ABTS (Southern
Biotech) as substrate and optical density values were recorded at
405 nm.
Flow cytometry
Flow cytometry was performed using standard protocols with
antibodies listed in Table 2 and a FACScan (Becton Dickinson) or
a CyAn ADP analyzer (Beckman Coulter). For intracellular
cytokine staining, Brefeldin A (3 mg/ml) was added to the cultured
cells for 2 hours before cells were subject to staining procedure.
Cell membranes were permeabilized for staining intracellular
molecules.
Adoptive transfer experiment
Male apoE (-/-) mice on regular chow received subcutaneous
immunization as described in previous paragraph and were
sacrificed at 13 weeks of age as donors. Splenocytes from the same
treatment group were pooled before cell isolation. Donor CD8
+ T
cells, CD4
+CD25
+ T cells or B cells were isolated using Dynabeads
FlowComp (Invitrogen) according to the manufacturer’s protocols.
CD4
+ T cells were negatively selected from the splenocytes
followed by positive selection of CD4
+CD25
+ cells. B cells were
negatively isolated whereas CD8
+ T cells were positively isolated
first and released from beads. The purity of pooled CD8
+ T cells,
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+CD25
+ T cells and B cells was ,90%. The isolated CD8
+ T-
cells (1610
6 cells/mouse), CD4
+CD25
+ T-cells (1610
5 or 3610
5
cells/mouse) or B cells (2610
7 cells/mouse) were then adoptively
transferred to naı ¨ve male apoE (-/-) recipient mice at 6–7 weeks of
age via tail vein injection.
For B cell transfer, the number of 2610
7 cells/mouse was chosen
based on two prior reports [35,36]. For CD4
+CD25
+ T cells
transfer, we chose 2 doses for our experiment based on published
literature [18,19,37]. For CD8
+ T-cells, 1610
6 cells was chosen
based ona reportfromthefieldofautoimmune disease[38].Wedid
not adoptively transfer CD4
+ T cells because naı ¨ve or antigen-
primed CD4
+ T cells are known to be pro-atherogenic [16,17].
Recipient mice were fed normal chow until 13 weeks of age
when chow was switched to high cholesterol diet until euthanasia
at 25 weeks of age. Aortas were harvested to assess the extent of
atherosclerosis.
KLH or Trinitrophenyl-lipopolysaccharide (TNP-LPS)
Immunization
KLH was chosen as a prototypical T cell dependent and TNP
as a T cell independent antigen. Male C57/BL6 mice on regular
chow received subcutaneous immunization with p210 conjugate or
adjuvant control as described in previous paragraphs for apoE (-/-)
mice. At 13 and 15 weeks of age mice were subcutaneously
immunized with 100 mg KLH (with alum as adjuvant) at injection
sites away from p210 sites or injected intraperitoneally with 100 mg
TNP-LPS (Sigma). KLH or TNP immunization was done in
separate groups of mice. Blood was collected via retro-orbital
puncture at euthanasia (16 weeks of age).
In vitro experiment
T cell proliferation assay. Male C57/BL6 mice fed regular
chow were immunized as detailed above for the apoE-/- mice.
WT mice were used to assure that potential antigenic exposure
from serum cholesterol as a confounding factor would be kept at a
minimum given the severe levels of hypercholesterolemia in
apoE-/- mice. At 15 weeks of age, 3 weeks after the second
booster, the mice were euthanized and the spleens harvested for
splenocyte isolation. Following RBC lysis, splenocytes pooled from
2 mice per group were labeled with CFSE (2 mMa t3 7 uC for
10 minutes). Equal numbers of cells were seeded into culture
dishes and the cells were stimulated with 50 mg/ml p210 in
complete medium (RPMI-1640 supplemented with 10 U/ml IL-
2). Cells were harvested after 5 days and stained with fluorescent
anti-CD4 or CD8b antibody and subjected to flow cytometry.
Generation of BM-derived dendritic cells (BMDCs). The
method for generating BMDC with GM-CSF was adapted from a
previous publication with modification [39]. Briefly, bone marrow
cells from femurs and tibiae of male apoE (-/-) mice were plated
into 10 cm culture plates (Falcon) with 20 ml complete RPMI-
1640 containing 10 ng/ml GM-CSF (R&D Systems) and 10 ng/
ml IL-4 (Invitrogen). Cells were washed and fed on day 3 and day
5 by removing the old medium followed by replenishing with fresh
culture medium with GM-CSF and IL-4. On day 8, the immature
DC appeared as non-adherent cells under the microscope and
harvested by vigorous pipetting and subcultured into new culture
plates with 2610
5 DCs in 1.5 ml medium.
CD8
+ T cell isolation and co-culture with dendritic
cells. Donor male apoE (-/-) mice for CD8
+ T cells were
immunized with PBS, cBSA/Alum, or cBSA/Alum/P210
according to the schedule described in earlier paragraphs and
splenocytes were harvested at 13 weeks of age. CD8
+ T cells were
negatively isolated using a CD8 selection Dynabeads kit
(Invitrogen) per manufacturer’s protocol. The selected CD8
+ T-
cells were then co-culture with DCs in a CD8:DC ratio of 3:1. A
series of pilot studies has been performed to determine the optimal
CD8:DC ratio for this assay. After co-culture for 4 hours, cells
were collected and processed for flow cytometric determination of
CD11c and 7-AAD by LSR II flow cytometer (BD Biosciences)
and data was analyzed with Summit V4.3 software. An additional
lytic assay was developed wherein BMDCs were transferred into
culture medium with 10% delipidated FBS (Cocalico Biologicals
Inc.) overnight prior to CD8 co-culture and the lytic assay
performed in 10% delipidated FBS medium. Lytic assay using
p210-loaded DCs was designed with FITC-labeled p210 using a
commercially available FITC labeling kit (Thermo Scientific).
BMDCs were loaded with FITC-labeled p210 (100 mg/ml) for
18 hours, determined by pilot experiments to be optimal for
maximal uptake. The cells were then washed and co-cultured with
CD8
+ T cells as described above for 4 hours. Lysis was then
assessed on FITC-gated DCs to assure that only p210-FITC
antigen-loaded DCs were included in the analysis. Dendritic cell
death without CD8
+ T cells in the co-culture was used as baseline
and percentage of specific lysis of cells was calculated using a
method described previously [40].
Statistics
Data are presented as mean 6 SD. Number of animals in each
group is listed in text or figure legend. Data were analyzed by
ANOVA followed by Newman-Keuls multiple group comparison,
or by t-test when appropriate. P,0.05 was considered as
statistically significant.
Supporting Information
Figure S1 T lymphocyte proliferation in response to
p210 stimulation. Histogram depicting cell proliferation of
CFSE-labeled splenocytes from the immunized groups in response
to stimulation with p210 (50 mg/ml). Stimulation with p210
increased CD4
+ T cell proliferation in both cBSA/alum (49.5%)
and p210/cBSA/alum (56.6%) compared to PBS (32.2%). CD8
+
T cell proliferation was highest in p210/cBSA/alum immunized
mice (40.1%) compared to PBS (16.7%) and cBSA/alum (25.8%).
(TIF)
Figure S2 Lymph node dendritic cell CD86 expression
one week after second booster. Significant increase in the
percentage of CD11c-gated CD86
2 cells (A) in the p210/cBSA/
alum group compared to PBS and cBSA/alum. Concomitant
decrease in CD11c-gated CD86
+ cells (B) in the p210/cBSA/alum
Table 2. Antibodies used for flow cytometry analysis.
Antigen Clone Type Supplier
CD4 GK1.5 FITC-Rat IgG2b, k BD Pharmingen
CD8b.2 53-5.8 FITC-Rat IgG1, k BD Pharmingen
CD25 PC61.5 PE-Rat IgG1, l eBioscience
IL-10 JES5-16E3 Percp-Cy5.5- Rat IgG2a, k eBioscience
IL-12 Clone C17.8 Percp-Cy5.5- Rat IgG2b, k eBioscience
CD11c HL3 FITC-Hamster IgG1, l BD Pharmingen
CD86 GL1 PE-Rat IgG2a, k BD Pharmingen
CD62L MEL-14 PE-Rat IgG2a, k eBioscience
CD69 H1.2F3 APC American hamster IgG eBioscience
doi:10.1371/journal.pone.0030780.t002
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was observed in the CD86 mean fluorescent intensity (MFI)
among the groups (C). *p,0.05; N=5 each group.
(TIF)
Figure S3 Aortic sinus phenotype of CD8
+ T cell
recipient mice. Aortic sinus plaque size was similar among
the recipient groups (A). Macrophage infiltration assessed by
MOMA-2 stain (B) was significantly reduced in both cBSA/alum
CD8
+ T cell and p210/cBSA/alum CD8
+ T cell recipient groups.
CD4
+ T cells were significantly reduced in recipient mice injected
with CD8
+ T cells from p210/cBSA/alum donors compared to
PBS or cBSA/alum group (C). No difference was observed in
CD8
+ T cells in the aortic sinus (D). *p,0.05 vs. PBS; {p,0.05 vs.
cBSA/alum; N=6–9 each group.
(TIF)
Figure S4 Adoptive transfer of B cells or CD4
+CD25
+ T
cells from immunized donor groups. Aortic atherosclerosis
was not significantly different among the recipients of B cells (A),
or CD4
+CD25
+ T cells at a dose of 1610
5 cells/mouse (B) or
3610
5 cells/mouse (C) adoptively transferred from donor mice of
the different immunized groups into naı ¨ve mice. N=9–13 each
group.
(TIF)
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